To be precise, the research questions are whether mutations in MT-CYB and MT-ATP6 are more prevalent or pathogenic in Bangladeshi COVID-19 patients than in healthy individuals, and whether these mutations are associated with disease severity or clinical outcomes. Here, MT-ATP6 is linked to COVID-19.